Internal Medicine Department, "Grigore T. Popa" University of Medicine and Pharmacy, Iași 700503, Romania.
Cardiology Department, Cardiovascular Diseases Institute "Prof. Dr. George I.M. Georgescu", Iași 700503, Romania.
Int J Mol Sci. 2020 Mar 11;21(6):1920. doi: 10.3390/ijms21061920.
Venous thrombosis is a common and potentially fatal disease, because of its high morbidity and mortality, especially in hospitalized patients. To establish the diagnosis of venous thrombosis, in the last years, a multi-modality approach that involves not only imaging modalities but also serology has been evolving. Multiple studies have demonstrated the use of some biomarkers, such as D-dimer, selectins, microparticles or inflammatory cytokines, for the diagnosis and treatment of venous thrombosis, but there is no single biomarker available to exclusively confirm the diagnosis of venous thrombosis. Considering the fact that there are some issues surrounding the management of patients with venous thrombosis and the duration of treatment, recent studies support the idea that these biomarkers may help guide the length of appropriate anticoagulation treatment, by identifying patients at high risk of recurrence. At the same time, biomarkers may help predict thrombus evolution, potentially identifying patients that would benefit from more aggressive therapies. This review focuses on classic and novel biomarkers currently under investigation, discussing their diagnostic performance and potential benefit in guiding the therapy for venous thrombosis.
静脉血栓形成是一种常见且潜在致命的疾病，由于其高发病率和死亡率，尤其是在住院患者中。为了确立静脉血栓形成的诊断，近年来，一种多模式方法不断发展，不仅包括影像学方法，还包括血清学方法。多项研究已经证明了一些生物标志物的使用，如 D-二聚体、选择素、微粒或炎症细胞因子，用于静脉血栓形成的诊断和治疗，但没有单一的生物标志物可专门用于确认静脉血栓形成的诊断。鉴于静脉血栓形成患者的管理和治疗持续时间存在一些问题，最近的研究支持这样一种观点，即这些生物标志物可以通过识别有高复发风险的患者，帮助指导适当抗凝治疗的时间。同时，生物标志物可能有助于预测血栓的演变，有可能识别出需要更积极治疗的患者。这篇综述重点介绍了目前正在研究的经典和新型生物标志物，讨论了它们在指导静脉血栓形成治疗方面的诊断性能和潜在益处。
